Fishawack provides fully-integrated, cross-border services to global pharmaceutical organisations. It provides a variety of medical communications, market access and pharmacovigilance services to clients to drive the commercialisation of drug compounds. Its services are typically provided from phase II/III clinical trial stage through to post-approval and last for the full lifecycle of the patents on compounds.
Fishawack is a specialist provider of scientific communications services to global pharmaceutical companies.
In January 2017 LDC backed the management buyout of Fishawack in a deal that values the business at £38million. LDC has committed further equity to accelerate Fishawack’s growth strategy, including potential acquisitions.
The investment is a tertiary buyout and will enable the Management team to accelerate its buy and build strategy through a number of targeted acquisitions over the medium term, in addition to supporting the growth of current client relationships.
In July 2017 Fishawack announced its first acquisition since the buyout, with the acquisition of US-based Carling Group of Companies. The Group includes Carling Communications, a full-service healthcare marketing and communications agency, and MCME Global, the specialist provider of medical education services. Both businesses are headquartered in San Diego.
We are an ambitious team and want to build on this further, continuing to strengthen our market-leading proposition and further building our presence internationally. In LDC we have a partner that is not only able to provide the financial backing we need to do this, but one that also has a strong track record in the pharmaceutical sector. Oliver Dennis, CEO, Fishawack